bioMerieux SA · EURONEXT:BIM
bioMerieux SA — H1 2004 Earnings Presentation
34 slides from bioMerieux SA's earnings presentation, Nov 12, 2004
Slide 1: 2004 First Half Results
BIOME|RIEUX 2004 First Half Results
Slide 2: Disclaimer
Disclaimer The present presentation contains information, assumptions and estimates that were used to determine these objectives. They are subject to change or modification due to economic, financial and competitive uncertainties in France or in other countries. Further information regarding these a
Slide 3: Table of contents
Table of contents 1. Introduction 2. Activity update 3. Financial results 4. Summary and perspectives 2
Slide 4: bioMérieux's Shareholder Structure
bioMérieux’s Shareholder Structure(1) ACCRA ACCRA (Mérieux (Mérieux Family) Family) 58,9% 12,9% Other Investors (2) Other Investors (2) 26,1% Free Float 2,1% Employees (3) Employees (3) and and Others Others (1) Post Employees Offering and exercise of the over-allotment option (2) GIMD, Banque de Vi
Slide 5: A tailored corporate governance
A tailored corporate governance • Completion of the Board of Directors : Ø 4 independant directors out of 9 Ø From now on, a board comprised of : Mr Alain Mérieux, Christophe Mérieux, Alexandre Mérieux, Philippe Villet, the TSGH company, Mr Georges Hibon, Michele Palladino, Michel Angé and the GIMD
Slide 6: Mission Statement
Mission Statement n Remain a biology company n Global leader in in vitro diagnostic at the Vision forefront of worldwide infectious disease prevention and treatment n Contributing to enhance public health 5
Slide 7: Table of contents
Table of contents 1. Introduction 2. Activity update 3. Financial results 4. Summary and perspectives 6
Slide 8: In Vitro Diagnostic: Increasing Role in Medicine and Industry
In Vitro Diagnostic: Increasing Role in Medicine and Industry In vitro diagnostic identifies and quantifies bacteria, viruses, proteins, markers, etc. in biological samples Prescription of Biological Analysis Reagents Prévention Instruments Private or hospital Results Therapy MEDICAL PHYSICIAN Softw
Slide 9: First half sales of 461 M€: A 6.9% organic growth rate
First half sales of 461 M€: A 6.9% organic growth rate (1) … Geographical breakdown Growth rates (1) of sales LatAm 7% Europe (2) +4.5% AsPac 9% North +8.9% Am AsPac +11.9% NorthAm 26% Europe (2) LatAm +12.7% 58% Reported Sales: +3% (1) Constant currency growth (2) Including the Middle-East and Afri
Slide 10: … on our two fields of applications …
… on our two fields of applications … CLINIC INDUSTRY 12.6% of sales 12.1% Activity of sales Activity Currency +24.2 M€ Currency +6.6 M€ Sales -15.1 M€ -2.3 M€ Sales Sales 402.4 M€ Sales -4.3% +12.3% 58.2 M€ 393.3 M€ -3.8% +6.1% 53.9 M€ june 2003 june 2004 june 2003 june 2004 9
Slide 11: …driven by the strategic segments
…driven by the strategic segments Breakdown of sales per technologies at 30 June 2004 Industrial Applications 58 M€ Other clinical lines 43 M€ Bactério- Clinical Applications Molecular Biology 12 M€ 403 M€ logy Haemostasis 25 M€ 208 M€ Immunoassays 115 M€ Clinical Applications : Bacteriology + 8% Im
Slide 12: A continuous geographical expansion
A continuous geographical expansion Sales by regions at 30 June 2004 Europe 267 M€ North America 120 M€ Shanghai Shanghai Asia Pacific 43 M€ Latin America 31 M€ 11
Slide 13: A growing installed base
A growing installed base Breakdown of sales (Equipments, reagents, service) (as % of total) 31/12/2003 30/06/2004 Reagents 84.5% 85.7% Equipments 11.4% 10.2% Service 4.1% 4.1% TOTAL 100% 100% More than 1900 new equipments installed on the first half 12
Slide 14: Products launched over the period
Products launched over the period 19 new products launched VIGI@CT VIGI@CT Software Software MDA MDA MiniMag VIDAS VIDAS PC PC Software MiniMag Software Software Software DA DA VINCI VINCI BacT/Alert BacT/Alert Observa Observa APIWEB APIWEB VITEK2 VITEK2 Software Software Software Software Software
Slide 15: Activity: other key events
Activity : other key events n South Africa : securing the NHLS tender n Status of regulatory affairs with the Food and Drug Administration n Capital Expenditures : Ø Molecular Biology in Grenoble and Durham (USA) Ø Petri dishes manufacturing in Craponne (Lyon area) Ø European logistic center for ins
Slide 16: Table of contents
Table of contents 1. Introduction 2. Activity update 3. Financial results 4. Summary and perspectives 15
Slide 17: Consolidated income statement
Consolidated income statement In millions of € 30/06/2004 30/06/2003 Growth 31/12/2003 Revenues 461 447 +3 % 915 Operating income 60 (1) 49 (2) +23 % 102 as % of revenues 13.1% 11.0% 11.2% Cash net income 34 29 +18 % 61 as % of revenues 7.3% 6.4% 6.7% Net income 32 26 +23 % 55 as % of revenues 6.9%
Slide 18: A significant increase of the operating income
A significant increase of the operating income Productivity +5.1 M€ Activity +3.8 M€ Operating Non-recurring income items +2.5 M€ 60.4 M€ Operating income +23% 49 M€ June 2003 June 2004 17
Slide 19: Decrease of non-recurring items
Decrease of non-recurring items Productivity +5.1 M€ Activity +3.8 M€ Operating Non-recurring income items +2.5 M€ 60.4 M€ Operating income 2003 : Rockland shutdown 49 M€ 2004 : - IPO costs - Grenoble June 2003 June 2004 18
Slide 20: Organic growth
Organic growth Productivity +5.1 M€ Activity +3.8 M€ Operating Non-recurring income items +2.5 M€ 60.4 M€ Operating income A 6.9% organic growth of sales x 49 M€ Operating margin as at 30 June 2003 before non-recurring items June 2003 June 2004 19
Slide 21: Productivity Gains
Productivity Gains Productivity +5.1 M€ Activity +3.8 M€ Operating Non-recurring income items +2.5 M€ 60.4 M€ Operating Gross margin improvements: income • 2003 Restructurations 49 M€ • Productivity • Favourable FX effects June 2003 June 2004 20
Slide 22: Tight control of operating expenses
Tight control of operating expenses Productivity +5.1 M€ Activity +3.8 M€ Operating Non-recurring income items +2.5 M€ 60.4 M€ Operating • Increased R&D efforts income • Stability of other operating expenses (as % of sales) 49 M€ • Increase of net received royalties June 2003 June 2004 21
Slide 23: A sustained growth of the net income
A sustained growth of the net income -0.7 M€ -4.3 M€ Financial Income +11.4 M€ expenses tax -0.4 M€ Operating Goodwills & income Others Net income Net income +23% 31.7 M€ 25.7 M€ Juin 2003 Juin 2004 22
Slide 24: A sustained growth of the net income
A sustained growth of the net income -0.7 M€ -4.3 M€ Financial Income +11.4 M€ expenses tax -0.4 M€ Operating Goodwills & income Others Net income Net income 31.7 M€ • Decrease of the average debt and of the cost of • Average tax rate: 39% 25.7 M€ debt • Tax rate w/o loss-making • Other non-recurrin
Slide 25: A significant free cash flow generation
A significant free cash flow generation Instruments (net) Net income 16.1 M€ 31.7 M€ Industrial Capex 14.3 M€ WCR & Pre-IPO group others reorganisation Depreciation, Amortization 22.6 M€ & others Free 41.7 M€ Cash-Flow Dividend 20.4 M€ 29.9 M€ Debt 3.4 M€ TSGH–NBMA 6.1 M€ 24
Slide 26: A solid financial situation
A solid financial situation Goodwill 66 M€ Instruments 64 M€ Shareholders Equity Other 354 M€ assets GEARING 52% 251 M€ Working capital Financial debt 157 M€ 184 M€ 25
Slide 27: Table of contents
Table of contents 1. Introduction 2. Activity update 3. Financial results 4. Summary and perspectives 26
Slide 28: Summary and perspectives 2004
Summary and perspectives 2004 First half 2004: n Good results and a solid financial situation For the whole 2004 fiscal year: n Sustained business: Ø increase in growth rate sales (excluding currency effects) in line with that of the past two years n Significant improvement in operating margin: Ø de
Slide 29: Our future announcements
Our future announcements n Revenues Q3 2004 : 20 October 2004 n Revenues Q4 2004 : 19 January 2005 28
Slide 30: BIOMÉRIEUX
BIOME|RIEUX
Slide 31: Appendices
Appendices 1. Growing Market and Attractive Business Model 2. Sustained Market Growth 3. Global, Consolidated Market 30
Slide 32: Growing Market and Attractive Business Model
Growing Market and Attractive Business Model n Clinical diagnostic focused on infectious diseases and key Positive pathologies Market Ø Structural growth factors are increasing IVD needs Drivers for – Demographic (e.g. ageing population) the Two Applications – Healthcare-related (e.g. resistance to
Slide 33: Sustained Market Growth
Sustained Market Growth Clinical IVD Market Has Doubled Growth Prospects in IVD Market in Each of the Last Two Decades 2003-2008E CAGR X2 >10% X2 €22bn €11bn 4-5% €6bn 1980 1990 2002 Clinical Industrial Applications Applications Sustained growth driven by increasing IVD needs and new technologies So
Slide 34: Global, Consolidated Market
Global, Consolidated Market IVD IVD Market Market Breakdown Breakdown by by Geography Geography n Europe and North America Rest of are the main regional markets Latin the World Ø 4% annual growth between 1998 and 2002 America 8% 4% n Other regions experience higher Asia growth rates Pacific North Ø